Skip to content

Prog Neuropsychopharmacol Biol Psychiatry

ISSN 0278-5846; 1878-4216;

2 papers in the library · publishing 2025-2026

Papers

Psychedelic-induced behavioral and developmental effects on zebrafish: a systematic review.

Prog Neuropsychopharmacol Biol Psychiatry October 20, 2025 Arthur L. De Oliveira, Danielle P. De Oliveira, Rafael G. Dos Santos et al.

A systematic review of 13 studies examined the developmental toxicity and behavioral effects of psychedelics in zebrafish. Substances included ayahuasca, DMT, ibogaine, LSD, MDMA, mescaline, noribogaine, psilocybin, and psilocin. Overall, psychedelics did not cause morphological abnormalities in embryo-larvae, though ayahuasca induced edemas and increased mortality at high concentrations. Ibogaine, MDMA, and LSD were linked to locomotor impairments after developmental exposure. DMT, psilocybin, and psilocin had anxiolytic effects on larvae, while LSD, MDMA, mescaline, and noribogaine reduced anxiety in adult fish. The findings suggest a safe toxicological profile at low concentrations, but whether they cause neurodevelopmental deficits in offspring remains unclear.

DOI: 10.1016/j.pnpbp.2025.111534 Zebrafish Psychedelics Behavior Development +1

Psychedelics for the management of symptoms of traumatic brain injury: Findings from the global psychedelic survey.

Prog Neuropsychopharmacol Biol Psychiatry January 30, 2026

People with traumatic brain injury who used psychedelics reported fewer symptoms of depression, anxiety, and post-traumatic stress than those who did not. The analysis of data from the Global Psychedelic Survey suggests that psychedelic use is associated with better mental health outcomes in this population, though the cross-sectional design cannot establish causation.

DOI: 10.1016/j.pnpbp.2026.111624